(Q37181235)

English

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.

scientific article published on 25 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

S Tariq Mahmood

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Samuel Agresta

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Carlos E Vigil

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Xiuhua Zhao

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Gina D'Amato

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ciara E Calitri

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Michelle Dean

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Christopher Garrett

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Michael J Schell

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Scott Antonia

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Alberto Chiappori

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

0 references

publication date

25 March 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

International Journal of Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

129

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1963-1969

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

Sunitinib: from rational design to clinical efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

6 September 2017

Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

14 September 2017

Combination chemotherapy for soft-tissue sarcomas: A phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

28 September 2017

Platelet-derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

26 June 2018

Soft tissue sarcoma trials: one size no longer fits all.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

3 September 2018

Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

3 September 2018

Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

3 September 2018

What price Kaplan-Meier?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3776586

3 September 2018

The Price of Kaplan–Meier

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25843

21 January 2018

Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade

1 reference

https://pubmed.ncbi.nlm.nih.gov/21154746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/21154746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/21154746

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/IJC.25843

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21154746%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37181235&oldid=1532710333"